CBI-1214 for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called CBI-1214, which is designed to help your immune system attack cancer cells. It is for people with advanced colorectal cancer that has not responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a specific type of colorectal cancer called MSS or MSI-L (your doctor can check this).
- You have already tried at least one standard treatment for your cancer, and it didn't work or stopped working.
- If your tumor has certain genetic changes (like BRAF or HER2), you must have already tried the targeted therapy for that change.
- You can provide a sample of your tumor tissue from a past biopsy or be willing to have a new biopsy.
- You do not have untreated brain metastases, an active autoimmune disease needing treatment in the past 2 years, or certain serious infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called RBS2418 for people with advanced colorectal cancer that has spread and is getting worse, even after other treatments have stopped working. The goal is to see if RBS2418 can help control the cancer.
This trial tests a new drug called CC-3, which is a type of antibody designed to help your immune system attack colorectal cancer cells. It is for people whose cancer has spread and who have already tried several standard treatments.
This early-stage trial tests a new drug called IBI3028 in people with advanced cancers that cannot be removed by surgery or have spread. The study aims to find the right dose and understand how the drug works in your body.
This trial tests a new drug combination for advanced colorectal cancer that has not gotten better with standard chemotherapy. It is for people whose tumors have normal RAS and BRAF genes, and it adds a new type of medicine (HCB101) to a common chemotherapy plus targeted therapy regimen.
This is an early-stage study testing a new drug (IM-1617) for advanced solid cancers that have not responded to standard treatments. The drug combines an antibody with a cancer-killing agent and may help people whose cancer has progressed despite prior therapy.
This study tests a new combination therapy (IBI363 with other drugs) for advanced colorectal cancer that is pMMR/MSI-L/MSS. It aims to understand how the immune system around the tumor changes during treatment.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.